Intérêt de la tomographie par émission de positons au fluorodéoxyglucose 18 dans la détection des neurofibrosarcomes au cours de la neurofibromatose de type 1

Bensaid, B.; Giammarile, Francesco; Mognetti, Thomas; Galoisy-Guibal, L; Pinson, Stéphane; Drouet, A.; Combemale, P.

doi:10.1016/s0151-9638(07)92528-4

Cited by 22 publications

(9 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2007, Bensaid et al [13] investigated the usefulness of FDG-PET in detection of MPNST in 38 patients with NF1. Forty-nine suspected MPNSTs were included in the study.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Usefulness of Whole-Body Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Patients with Neurofibromatosis Type 1: A Systematic Review

Treglia

Taralli²,

Bertagna³

et al. 2012

Radiology Research and Practice

View full text Add to dashboard Cite

Aim. To systematically review the role of positron emission tomography (PET) with fluorine-18-fluorodeoxyglucose (FDG) in patients with neurofibromatosis type 1 (NF1). Methods. A comprehensive literature search of published studies regarding FDG-PET and PET/CT in patients with NF1 was performed. No beginning date limit and language restriction were used; the search was updated until December 2011. Only those studies or subsets in studies including whole-body FDG-PET or PET/CT scans performed in patients with NF1 were included. Results. We identified 12 studies including 352 NF1 patients. Qualitative evaluation was performed in about half of the studies and semiquantitative analysis, mainly based on different values of SUV cutoff, in the others. Most of the studies evaluated the role of FDG-PET for differentiating benign from malignant peripheral nerve sheath tumors (MPNSTs). Malignant lesions were detected with a sensitivity ranging between 100% and 89%, but with lower specificity, ranging between 100% and 72%. Moreover, FDG-PET seems to be an important imaging modality for predicting the progression to MPNST and the outcome in patients with MPNST. Two studies evaluated the role of FDG-PET in pediatric patients with NF1. Conclusions. FDG-PET and PET/CT are useful methods to identify malignant change in neurogenic tumors in NF1 and to discriminate malignant from benign neurogenic lesions.

show abstract

“…In 2007, Bensaid et al [13] investigated the usefulness of FDG-PET in detection of MPNST in 38 patients with NF1. Forty-nine suspected MPNSTs were included in the study.…”

Section: Resultsmentioning

confidence: 99%

“…PET scan thus demonstrated a sensitivity and negative predictive value of 100%, specificity of 86%, and a positive predictive value of 50%. This study demonstrated the value of FDG-PET in detecting MPNST, even though false positive results require medical-surgical confirmation before any therapeutic decision [13]. …”

Section: Resultsmentioning

confidence: 99%

Usefulness of Whole-Body Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Patients with Neurofibromatosis Type 1: A Systematic Review

Treglia

Taralli²,

Bertagna³

et al. 2012

Radiology Research and Practice

View full text Add to dashboard Cite

show abstract

“…Bensaid et al showed a 100% negative predictive value (NPV) for malignancy using FDG-PET scans in NF1 patients with symptomatic lesions [9]. Specificity was 86%, meaning that there would be false-positive scans; however, the NPV provides increased confidence in diagnosis of benign tumours when PET scan is negative [9].…”

Section: Discussionmentioning

confidence: 99%

“…Specificity was 86%, meaning that there would be false-positive scans; however, the NPV provides increased confidence in diagnosis of benign tumours when PET scan is negative [9]. PET/CT also proved useful in biopsy planning where the most metabolically active area, reflecting the highest grade of tumour, can be biopsied [1, 10].…”

Section: Discussionmentioning

confidence: 99%

Plexiform Neurofibroma of the Wrist: Imaging Features and When to Suspect Malignancy

Gosein

Ameeral

Banfield

et al. 2013

Case Reports in Radiology

View full text Add to dashboard Cite

Plexiform neurofibromas are essentially pathognomonic for neurofibromatosis type 1 (NF1), occurring when there is diffuse involvement along a nerve segment and its branches. Transformation into a malignant peripheral nerve sheath tumour (MPNST) is a major cause of mortality in NF1 patients. These tumours are highly aggressive and particularly difficult to diagnose in NF1 patients due to the clinical overlap between benign and malignant lesions. We present a case of a plexiform neurofibroma and discuss the typical imaging characteristics on ultrasound, CT, and MRI, including the target sign and continuity with the parent nerve. Certain imaging features should raise suspicion for malignancy however, these modalities may not always reliably differentiate between benign and malignant lesions. Recent studies show a very high negative predictive value for FDG-PET making it quite useful in excluding malignancy. In positive scans, PET/CT aids in guiding biopsy to the most metabolically active area of the tumour.

show abstract

“…1-3 However, the characterization of PNSTs by anatomic imaging methods and clinical features is challenging, given that the features of various benign tumors are shared, 4 and the features of benign PNSTs and MPNSTs overlap. Recent literature suggests some specific anatomic imaging features with MR imaging 5-8 and specific metabolic imaging features with PET 9-13 to be associated with malignant disease in PNSTs. Yet, noninvasive characterization of malignant disease remains problematic, especially in patients with neurofibromatosis type 1 (NF-1), who may have both benign and malignant tumors simultaneously and have greater risk for the development of MPNSTs than the general population.…”

mentioning

confidence: 99%

Characterization of Peripheral Nerve Sheath Tumors with 3T Proton MR Spectroscopy

Fayad

Wang²,

Blakeley

et al. 2013

American Journal of Neuroradiology

View full text Add to dashboard Cite

Background and Purpose The characterization of peripheral nerve sheath tumors is challenging. The purpose here was to investigate the diagnostic value of quantitative proton MR spectroscopy at 3T for the characterization of peripheral nerve sheath tumors as benign or malignant, compared with PET. Materials and Methods Twenty participants with 24 peripheral nerve sheath tumors underwent MR spectroscopy by use of a point-resolved sequence (TE, 135 ms). Six voxels were placed in 4 histologically proven malignant peripheral nerve sheath tumors and 22 voxels in 20 benign peripheral nerve sheath tumors (9 histologically proven, 11 with documented stability). The presence or absence of a trimethylamine signal was evaluated, the trimethylamine concentration estimated by use of phantom replacement methodology, and the trimethylamine fraction relative to Cr measured. MR spectroscopy results for benign and malignant peripheral nerve sheath tumors were compared by use of a Mann-Whitney test, and concordance or discordance with PET findings was recorded. Results In all malignant tumors and in 9 of 18 benign peripheral nerve sheath tumors, a trimethylamine peak was detected, offering the presence of trimethylamine as a sensitive (100%), but not specific (50%), marker of malignant disease. Trimethylamine concentrations (2.2 ± 2.8 vs 6.6 ± 5.8 institutional units; P < .049) and the trimethylamine fraction (27 ± 42 vs 88 ± 22%; P < .012) were lower in benign than malignant peripheral nerve sheath tumors. A trimethylamine fraction threshold of 50% resulted in 100% sensitivity (95% CI, 58.0%–100%) and 72.2% (95% CI, 59.5%–75%) specificity for distinguishing benign from malignant disease. MR spectroscopy and PET results were concordant in 12 of 16 cases, (2 false-positive results for MR spectroscopy and PET each). Conclusions Quantitative measurement of trimethylamine concentration by use of MR spectroscopy is feasible in peripheral nerve sheath tumors and shows promise as a method for the differentiation of benign and malignant lesions. Trimethylamine presence within a peripheral nerve sheath tumor is a sensitive marker of malignant disease, but quantitative measurement of trimethylamine content is required to improve specificity.

show abstract

Intérêt de la tomographie par émission de positons au fluorodéoxyglucose 18 dans la détection des neurofibrosarcomes au cours de la neurofibromatose de type 1

Cited by 22 publications

References 32 publications

Usefulness of Whole-Body Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Patients with Neurofibromatosis Type 1: A Systematic Review

Usefulness of Whole-Body Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Patients with Neurofibromatosis Type 1: A Systematic Review

Plexiform Neurofibroma of the Wrist: Imaging Features and When to Suspect Malignancy

Characterization of Peripheral Nerve Sheath Tumors with 3T Proton MR Spectroscopy

Contact Info

Product

Resources

About